“…Controlled clinical trials have demonstrated the superior efficacy of escitalopram over citalopram despite equivalent doses containing a corresponding number of S -CIT molecules in both drugs [1,5,8,18,19,25] . As a result, the interindividual and dosedependent variations of the enantiomer ratios may theoretically infl uence the clinical effi cacy of a given dose of racemic CIT in the individual due to the antagonistic role of the R -enantiomer [14,20] , which may further partially explain the inconsistent and confl icting data on the relationship between serum CIT and clinical response [7,8,22] .…”